The Biotechnology Industry Organization (BIO) is grateful for the opportunity to provide comments on India's Draft National IPR Strategy, hereafter referred to as "Draft Strategy". Moreover we applaud the Government of India (GOI) for taking on the difficult but important task of improving India's intellectual property (IP) system to spur innovation. It is in the interest of BIO and its many members to pass along the experiences and wisdom gained through three decades of experience in bringing new biotechnology products to market. India is at the cusp of this new and promising industry and it is in this spirit that these comments are provided to the Government of India .
Since its inception roughly 30 years ago, the biotechnology industry has spurred the creation of more than one million direct jobs, and millions of related jobs in countries throughout the world. Today, there are more than 200 biologic medicines and vaccines that benefit millions of patients worldwide. More than 600 new biologic medicines are in development, including treatments for cancer, diabetes, cardiovascular disease, HIV/AIDS, Alzheimer's disease, and numerous rare conditions. These products are helping more than 325 million people worldwide. Another 400 biotechnology medicines are in the pipeline.
Biotechnology tests enhance our ability to better tailor patient care through greater precision in diagnosis, in many cases in a less invasive manner. Today, there are more than 1,200 molecular diagnostic tests being used in clinics around the world.
Biotechnology also holds great hope for feeding the world by increasing crop yields, preserving and improving soils, enhancing the control of pests, weeds and harmful diseases and producing more healthful food with enhanced vitamin and nutrient levels. Agricultural biotechnology has helped produce dramatic increases in yields of cotton, soybeans and corn -all staple crops that feed and clothe millions. These agricultural innovations are increasing food supplies, conserving natural resources of land water and nutrients, increasing farm income, and growing the economy worldwide.
Within the field of industrial biotechnology, companies are leading the way in creating both conventional and next generation advanced biofuels, which can be produced from forest residues, algae, municipal solid waste, or other renewable sources of biomass, without compromising the environment. In addition, industrial biotechnology helps make manufacturing processes cleaner and more efficient; creates new materials, food ingredients and other products; unlocks cleaner sources of energy; and reduces industrial waste. For example, biotechnology enzymes are used in such wide-ranging products as cheese, detergents, environmentally-friendly plastics and renewable fuels like cellulosic ethanol.
Developing a biotechnology product is a lengthy and expensive Endeavour. In the health sector, on average, it takes US$1.2 billion over a period of more than a decade to bring a new biopharmaceutical to market; for agricultural biotechnology it takes hundreds of millions of dollars and over a decade to develop a new product. Biotechnology companies-whether in the United States or in India-choose to make this investment when there is a reasonable expectation of a return on investment, although there is never a guarantee of success. However, if the product is successful, inventors want to ensure that they reap the benefits in recognition of the tremendous risks they had taken.
That is why Intellectual Property is so important. To raise the significant capital required for research and development, companies must first be able to assure investors that their patent portfolios are not at risk from competitors. No company--whether an SME or a multinational company--can afford to take such risks if its investment in ultimately successful products cannot be protected after it struggled through the arduous product development process. And thus, no company will, in the long term, view significant R&D investment in a country where patents can be easily swept aside, whether through a post-grant opposition or a compulsory license. This is particularly the case when other countries in the region provide stronger, more stable intellectual property protection.
India's Biotechnology Sector
The government of India has recognized the tremendous potential of biotechnology and has invested billions in biotechnology research. Many of India's premier institutions are developing biotechnology incubators to facilitate the development, manufacture and commercialization of research arising from this investment.
Today, India's biotechnology sector is a burgeoning one, with more than 325 companies, some having revenues in the billions of dollars. According to the 2012 BioSpectrum-ABLE (Association of Biotechnology Led Enterprises) Biotech Industry Survey, the industry grew by 24% in the last ten years, surging to $4 billion.
1 Analysts opine that given the right environment this growth can surge to 30%. If that happens, the industry will be a $100 billion giant by the year 2025. The Indian bioindustrial sector registered an eight percent growth in its revenues with total sales of $142 million. This increase in enzymes consumption is attributed to the rise in demand from the food, pharmaceutical, detergent and energy sectors. India both imports and exports enzymes for different purposes. India is on the cusp of biotechnology innovation, but as the Government has correctly recognized, it is not enough to invest in biotechnology research. India must improve the enabling environment necessary for biotechnology to flourish, a centerpiece of which is protection of intellectual property rights (IPR) .
The Biotechnology Business Model-Small and Medium Sized Enterprises
The key to success of the biotechnology industry -across of all its sectors -is a business model that is based on taking significant risks to develop products based on innovation. Specifically, the biotechnology business model is based on making significant investments (often hundreds of millions of U.S. dollars) in early stage research and development with the hope that some of these investments and efforts will yield a commercial product. On average, it takes more than 10 years to develop a biotechnology medicine or a plant improved through agricultural biotechnology from its inception to regulatory approval and finally to market launch. As mentioned above, the average, fully capitalized cost of developing a new medicine has been estimated at $1.2 billion and a new biotechnology derived plant product at $133 million. This model has worked despite the fact that the development process is long and that most biotechnology R&D investments and efforts do not result in a commercial product reaching the market primarily due to the strength of the patent system.
It is only by pushing scientific boundaries and taking risks that breakthrough inventions are discovered and converted into commercially viable products and by ensuring that the products or services that may eventually be marketed can be protected from unauthorized copying and use, companies can justify taking risks and making significant R&D investments. Introducing unpredictability by changing the availability of patent rights, or the conditions in which patent rights can be asserted, or threats of compulsory licensing will adversely affect the business environment that is so crucial to supporting innovation in the biotechnology sector. Such unpredictability will undoubtedly hinder India's efforts to nurture small-and medium-sized enterprises within its borders.
Patents in the life sciences sector protect the type of products and processes that are integral to small-and medium-sized companies doing business in the biotechnology sector. By enabling these companies to prevent the unauthorized use of the patented technology, companies can justify pursuing their research and development efforts. Indeed, it is the guarantee of securing and using rights in the future that companies rely upon to justify making investments in R&D today.
To illustrate the role of patents in the typical start-up biotechnology venture, consider the following example of biotechnology innovation in the health sector.
A researcher, typically in a university laboratory, discovers a gene which is expressed only by a particular type of cancer cell. This discovery can result in a variety of distinct research and development initiatives -ranging from diagnostic tools for detecting the presence of the gene or its expression product in test samples taken from patients, to therapeutic agents that selectively kill cells that express the gene or inhibit its expression. As soon as practical after the discovery of the gene and its practical value, patent applications must be filed. Filing the application early ensures that the researcher or its sponsor (a university or startup biotechnology company) can secure rights in the inventions that derive from the discovery, and permits the researcher to publish the results. The patents based on this early application will be used to justify the investment of millions of dollars into development of these diagnostic and therapeutic agents. Translating this initial discovery into a tangible product can take more than a decade of research and development and the investment of hundreds of millions of dollars. The exclusivity provided by patents issued from this early application of this technology provide investors with a more tangible right in the technology, and will be a key factor affecting funding of the business venture. A larger company will also consider the strength of patent rights when deciding whether to conduct clinical development of products discovered by any startup company or university that owns the patent. Such endeavor involves a significant likelihood of failure, and is fraught with other possible commercial setbacks. Further scientific advancements lead to additional innovation, which may be pursued in multiple aspects by different parties. The confidence that patent rights will protect products that are developed, propel the transfer of technology and collaboration on the research and development work that follows.
Given the importance of patent protection for biotechnology product development and commercialization, a streamlined process for patenting, and the appropriate scope and patentable subject matter protections are of great importance. In particular, in India, where both the public and private sectors have invested heavily in biotechnology, resulting in numerous promising discoveries in biofuels, healthcare and in agriculture, a patent framework that facilitates the translation of these discoveries to products will be of great value.
Nevertheless, both Indian and foreign companies which have filed patents in
India have experienced problems throughout the examination process as well as post patent grant.
BIO's Overall View of the Draft Strategy
BIO supports the overall goal of the Draft Strategy to raise awareness of the importance of, and respect for IPR and to encourage IP creation in both private and public institutions. BIO specifically supports the Government's goals to set up "facilitation centers" so that institutions can identify patentable matter and file for IP protection. Successful efforts in this area have been made in several other countries including in the U.S. where such centers are part of "incubators" co-located with research institutions and economic development centers. In this regard, we recommend a review of the recent Battelle report 3 which provides a detailed look and several examples of ways such "centers" can assist start-up companies to do research in wet-labs, patent inventions, find partners, investors and the like.
BIO also supports the Government's proposal to create favorable tax treatment for R&D expenditures. Small companies generally register net operating losses in their first years. Moreover, they continue these losses, even several years after companies commercialize products. This is because of the significant upfront cost of investment that must be recouped in order to make a company profitable, and sustainable. 4 Accordingly, tax relief in this area can provide significant incentive. However, in order for this incentive to work, it must be linked to other improvements including in the IP regime.
BIO further supports initiatives to better leverage academia and public research laboratories to create and commercialize research through training researchers and generating overall awareness of the importance of IP creation and licensing.
In this regard, BIO supports the Draft Strategy's proposal to include "technology In this regard, BIO suggests that the development of guidelines coupled with training on patentability criteria would help alleviate some of the disparities that patentees face on a regular basis.
 Furthermore, BIO has heard from members that delays in processing applications coupled with the drawn out opposition procedures is a significant problem for patentees. This is exacerbated by the fact that the timelines and processes for opposition procedures are not well-defined.  India's Patents Act requires applicants to disclose the source and geographical origin of biological materials used to make an invention that is the subject of a patent application. These special disclosure requirements impose unreasonable burdens on patent applicants, subjecting valuable patent rights to great uncertainty. Under the Indian law, the failure to identify the geographical source of a biological material and its origin may be a basis for opposition or revocation proceedings; however, the necessary relationship to the patented invention is not clear.
Oftentimes patentees have obtained samples or materials from universities or in partnership with universities or depositories. Identifying the source of these materials is may be impossible as many may have been obtained decades prior. At the USPTO roundtable interested parties were informed that for the purpose of the IPO, identification of the source is sufficient. However, the law requires both the source and origin to be disclosed. These requirements pose unacceptable risks for patent applicants and undermine the incentives of the patent system to promote research and innovation in the biotechnology sector.
 Indian patent law prohibits or limits the ability of biotechnology companies to patent certain broad classes of fundamental innovations. While some or all of the above issues may be within the purview of the authors of the Draft Strategy to address, there are other concerns described below which fall outside of the IPO's purview. However, it is important for the IPO to understand the challenges being experienced by the biotechnology sector as they go through their research and development process. Below are some areas of concern.
Courts
Indian law recently recognized patent protection for pharmaceutical compounds.
The standards for claim interpretation, trial, and enforcement of injunctions are still under development. Generally, the courts lack uniform standards for issuing injunctions and have not given deference to the determinations of the Patent
Office. The courts have often not enforced injunctions to protect patents issued to foreign applicants. Indian courts also often decline to uphold patents that have been granted with the same or similar claims in jurisdictions with higher patentability requirements. The courts have also declined to consider granted patents when deciding whether to approve marketing applications by generics if a patent is being tested in the courts or in opposition.
Recent case law developments have drawn concern from our member companies in the areas of obviousness, novelty and rejection of new methods for using known compounds. For example, the interpretation of the obviousness standard for dosage forms and other similar inventions has drawn concern. 7 The second issue involves the interpretation of the novelty and obviousness standards in the context of an enantiomer product. 8 The final issue is the rejection of any applications for new methods of use for known compounds.
9
Biotechnology companies would find it helpful if the Government of India partnered with other patent-friendly nations to conduct training for Indian court officials to help handle the various issues involved in patent cases, which are often difficult and require specialized training. Such training would be beneficial to the Indian court system to help them make consistent decisions and create uniform standards for enforcement. Consolidating patent cases into a few specialized patent courts might also help these issues as it would allow judges to gain expertise in a very new and complex area of law.
Drug Regulatory Body
BIO also supports the Draft Strategy's goal of strengthening enforcement of IP.
We 
Conclusion
Once again, BIO is grateful for the opportunity to provide comments on the Draft National IP Strategy, and commends the Government of India for taking on the laudable goal of strengthening the Indian IP system in an effort foster ). E.g., see safeguard (xi), which states that "[i]n cases where repeating the clinical trials for a drug is not considered essential, the Regulatory Authority may allow marketing approval to subsequent applicants of a drug similar to an earlier approved drug by placing reliance on the first applicant's undisclosed data." economic growth, innovation and IP creation. We believe that the biotechnology sector in India has significant contributions to make to this effort, and stands ready to work with the Government to meet its overarching goals.
For additional information about BIO, the biotechnology industry in India and any issues raised in this paper, please don't hesitate to contact me at lfeisee@bio.org.
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